In a world where more than 500 million people battle known and undiagnosed diabetes, Dexcom stands out. This trailblazer in continuous glucose monitoring is on track for substantial growth amid evolving diabetes detection and treatment. In this episode, Senior Research Analyst Jenny Goldsmith, CFA details how Dexcom’s state-of-the-art software and predictive algorithms are revolutionizing diabetes care and why Goldsmith believes Dexcom’s distinctive edge translates into investment opportunities.

www.sandscapital.com/WMM-Disclosure